BACKGROUND:Several studies have shown that postplacental intrauterine device (IUD) insertion is a safe, convenient, and effective option for postpartum contraception. Of the prior studies performed, few involve ultrasound-guided insertion, none involve the levonorgestrel intrauterine system, and none of the prior studies take place in a United States residency program. OBJECTIVE: To assess the safety and feasibility of ultrasound-guided postplacental insertion of levonorgestrel intrauterine system (Mirena) in a U.S. residency program. METHODS: Levonorgestrel intrauterine system IUDs were inserted within 10 minutes of placental delivery after vaginal delivery via either ringed forceps or hand technique. All insertions were ultrasound-guided. Of the 30 subjects that were enrolled, 20 received an levonorgestrel intrauterine system IUD. Subjects were examined at 4 weeks postpartum and 10 weeks postpartum for evidence of expulsion or infection. RESULTS: Of the subjects who have been followed to date, none have had evidence of intrauterine infection. There have been 2 expulsions, giving an expulsion rate of 10% at 10 weeks postpartum. CONCLUSION: This pilot study suggests that ultrasoundguided postplacental insertion of Mirena IUDs is a feasible, safe option for postpartum contraception in a U.S. residency program. OBJECTIVE:To compare the effects on ovulation incidence of 2 dosing regimens (21-and 24-day) of an oral contracep-tive (OC) containing ethinyl estradiol (EE) 20 g/drospirenone 3 mg following predefined dosing errors. METHODS: This double-blind, randomized study recruited women (18 -35 years) who had ovulated and had a follicular diameter of 15 mm or greater on day 23 during the cycle before starting study treatment. Women received 3 treatment cycles of EE 20 g/drospirenone 3 mg in a 21/7 (21 active/7 placebo) or 24/4 day (24 active/4 placebo) regimen. In treatment cycle 3, the initial 3 tablets in each pack in both dosing regimens were placebo. Ovarian activity was classified via Hoogland score. Secondary end points included serum concentrations of 17  estradiol, luteinizing hormone (LH), and follicle-stimulating hormone (FSH). RESULTS: After 3 treatment cycles, the odds of having a lower Hoogland score with the 24-day regimen was 3.06 times higher (95% confidence interval 1.44 -6.65) than with the 21-day regimen. One ovulation was observed in the 24-day regimen (cycle 3), and 4 ovulations were observed in the 21-day regimen. More women in the 24-day regimen had Hoogland scores of 1 (no follicular activity) (51.9% versus 28.8%). Similar levels of serum estradiol, LH, and FSH suppression were achieved with both regimens, indicating good ovulation suppression. CONCLUSION: Both regimens demonstrated reliable ovulation inhibition, indicated by low Hoogland scores. Stronger suppression of follicular development was observed with the 24-day regimen when dosing errors were intentionally introduced. This should translate into improved contraceptive efficacy in clinical practice.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.